$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000153217613000008 Filed on May 03, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$439.7M	$231.8M
YoY Change	89.68%	106.58%
Cost Of Revenue	$28.02M	$12.30M
YoY Change	127.85%	2974.5%
Gross Profit	$411.6M	$219.5M
YoY Change	87.54%	96.32%
Gross Profit Margin	93.63%	94.69%
Selling, General & Admin	$77.26M	$58.43M
YoY Change	32.23%	149.69%
% of Gross Profit	18.77%	26.62%
Research & Development	$180.3M	$138.9M
YoY Change	29.84%	7.31%
% of Gross Profit	43.8%	63.27%
Depreciation & Amortization	$9.407M	$8.416M
YoY Change	11.78%	20.23%
% of Gross Profit	2.29%	3.83%
Operating Expenses	$257.6M	$197.3M
YoY Change	30.55%	29.12%
Operating Profit	$153.1M	$22.20M
YoY Change	589.38%	-154.15%
Interest Expense	$11.68M	$11.16M
YoY Change	4.61%	-401.62%
% of Operating Profit	7.63%	50.27%
Other Income/Expense, Net	-$11.22M	-$10.55M
YoY Change	6.34%	-1155.0%
Pretax Income	$141.8M	$11.65M
YoY Change	1117.33%	-126.66%
Income Tax	$42.96M
% Of Pretax Income	30.29%
Net Earnings	$98.87M	$11.65M
YoY Change	748.63%	-126.82%
Net Earnings / Revenue	22.49%	5.03%
Basic Earnings Per Share	$1.02	$0.12
Diluted Earnings Per Share	$0.90	$0.11
COMMON SHARES
Basic Shares Outstanding	96.88M shares	93.45M shares
Diluted Shares Outstanding	109.4M shares	107.7M shares

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$308.0M	$432.0M
YoY Change	-28.7%	91.15%
Cash & Equivalents	$180.4M	$394.6M
Short-Term Investments	$127.0M	$38.00M
Other Short-Term Assets	$159.0M	-$1.000M
YoY Change	-16000.0%	-109.09%
Inventory	$43.98M	$27.00M
Prepaid Expenses
Receivables	$703.9M	$238.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.307B	$697.0M
YoY Change	87.54%	113.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$392.4M	$370.0M
YoY Change	6.05%	3.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$347.0M	$255.0M
YoY Change	36.08%	-31.82%
Other Assets	$20.08M	$29.00M
YoY Change	-30.77%	61.11%
Total Long-Term Assets	$968.9M	$653.0M
YoY Change	48.37%	-12.7%
TOTAL ASSETS
Total Short-Term Assets	$1.307B	$697.0M
Total Long-Term Assets	$968.9M	$653.0M
Total Assets	$2.276B	$1.350B
YoY Change	68.59%	25.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.00M	$25.00M
YoY Change	0.0%	25.0%
Accrued Expenses	$121.0M	$81.00M
YoY Change	49.38%	107.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$197.2M	$160.0M
YoY Change	23.28%	42.86%
LONG-TERM LIABILITIES
Long-Term Debt	$461.0M	$440.0M
YoY Change	4.77%	176.73%
Other Long-Term Liabilities	$8.786M	$246.0M
YoY Change	-96.43%	-13.68%
Total Long-Term Liabilities	$8.786M	$686.0M
YoY Change	-98.72%	54.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$197.2M	$160.0M
Total Long-Term Liabilities	$8.786M	$686.0M
Total Liabilities	$869.7M	$846.0M
YoY Change	2.8%	52.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$418.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.406B	-$30.79M
YoY Change
Total Liabilities & Shareholders Equity	$2.276B	$1.350B
YoY Change	68.59%	25.7%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	$98.87M	$11.65M
YoY Change	748.63%	-126.82%
Depreciation, Depletion And Amortization	$9.407M	$8.416M
YoY Change	11.78%	20.23%
Cash From Operating Activities	$86.25M	-$87.04M
YoY Change	-199.09%	721.14%
INVESTING ACTIVITIES
Capital Expenditures	-$21.20M	-$11.10M
YoY Change	90.99%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$126.5M	$26.80M
YoY Change	-572.01%	-36.94%
Cash From Investing Activities	-$147.7M	$15.77M
YoY Change	-1036.73%	-22.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$12.96M	$31.83M
YoY Change	-59.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$11.52M	-$17.75M
YoY Change	-164.92%	-236.54%
NET CHANGE
Cash From Operating Activities	$86.25M	-$87.04M
Cash From Investing Activities	-$147.7M	$15.77M
Cash From Financing Activities	$11.52M	-$17.75M
Net Change In Cash	-$49.91M	-$89.03M
YoY Change	-43.93%	-492.18%
FREE CASH FLOW
Cash From Operating Activities	$86.25M	-$87.04M
Capital Expenditures	-$21.20M	-$11.10M
Free Cash Flow	$107.4M	-$75.94M
YoY Change	-241.49%	-754.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	145413000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	111345000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	38934000	USD
CY2013Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	24729000	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	703857000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	593207000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1166000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1644000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1763508000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1826075000	USD
CY2013Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	2293000	USD
CY2012Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	49078000	USD
CY2013Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3085000	USD
CY2012Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23448000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	53555000	USD
CY2012Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-98692000	USD
CY2013Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-12626000	USD
CY2012Q4	us-gaap	Assets Assets	2080490000	USD
CY2013Q1	us-gaap	Assets Assets	2275998000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	1206012000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	1307122000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	354990000	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	483142000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	66835000	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	149739000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	63442000	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	146953000	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	2786000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	3393000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	351565000	USD
CY2013Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	479528000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	354958000	USD
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	482313000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	702000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	1415000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	651000	USD
CY2013Q1	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	1259000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	702000	USD
CY2013Q1	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	1415000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	51000	USD
CY2013Q1	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	156000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	670000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	586000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	180362000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230276000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	394585000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	483610000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-89025000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-49914000	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	98396000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12176000	USD
CY2013Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	302268000	USD
CY2012Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	296518000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	29055000	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12298000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	286614000	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	209588000	USD
CY2012Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	39525000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33809000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	34391000	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125436000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	131822000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	99632000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	148134000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	192022000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	201319000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8416000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9407000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	99913000	USD
CY2013Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	98781000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2013Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.303
CY2013Q1	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.123
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19987000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32385000	USD
CY2013Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2293000	USD
CY2012Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities		USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	141831000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	11651000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14656000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42957000	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12710000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	32105000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	135312000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109518000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9126000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6470000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43660000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6661000	USD
CY2012Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	463000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	314000	USD
CY2013Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1890000	shares
CY2012Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2012Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	13630000	shares
CY2013Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10276000	shares
CY2013Q1	us-gaap	Interest Expense InterestExpense	11675000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	11160000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2570000	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6390000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	43977000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	28638000	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6315000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4862000	USD
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2013Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4600000	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	25061000	USD
CY2012Q1	us-gaap	Inventory Write Down InventoryWriteDown	1900000	USD
CY2013Q1	us-gaap	Inventory Write Down InventoryWriteDown	3200000	USD
CY2012Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	610000	USD
CY2013Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	456000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	835105000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	869650000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2275998000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2080490000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	197244000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163550000	USD
CY2013Q1	us-gaap	Licenses Revenue LicensesRevenue	5893000	USD
CY2012Q1	us-gaap	Licenses Revenue LicensesRevenue	5893000	USD
CY2013Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	127348000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	77819000	USD
CY2013Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	346607000	USD
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	271230000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17750000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11523000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147685000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15766000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87041000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	86248000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	11651000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	98874000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11219000	USD
CY2012Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10550000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	22201000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	153050000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22367000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19569000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23100000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20078000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	525000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-478000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	525000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-300000	USD
CY2012Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	6550000	USD
CY2013Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	6211000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7259000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8786000	USD
CY2013Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7174000	USD
CY2012Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2494000	USD
CY2012Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	49078000	USD
CY2013Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3085000	USD
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	180922000	USD
CY2012Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48569000	USD
CY2013Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	21203000	USD
CY2012Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	11055000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	56663000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	97142000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31828000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12964000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	54754000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	75853000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	379940000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	392378000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	649000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	500000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	180299000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	138862000	USD
CY2013Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	8494000	USD
CY2012Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	8186000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517054000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-418180000	USD
CY2012Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	85005000	USD
CY2013Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	99273000	USD
CY2013Q1	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. </font></div></div>
CY2012Q1	us-gaap	Revenues Revenues	231789000	USD
CY2013Q1	us-gaap	Revenues Revenues	439664000	USD
CY2012Q1	us-gaap	Royalty Revenue RoyaltyRevenue	477000	USD
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	851000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	318740000	USD
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	127931000	USD
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58428000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77260000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	53030000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	23244000	USD
CY2012Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan		USD
CY2013Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan		USD
CY2013Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9804000	USD
CY2012Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31746000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	1406348000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1245385000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-49078000	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	-30786000	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	18826000	USD
CY2013Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	21904000	USD
CY2013Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	19661000	USD
CY2013Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	16583000	USD
CY2012Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14288000	shares
CY2013Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12491000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109369000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107734000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93446000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96878000	shares
CY2013Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	10100000	USD
CY2012Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	8600000	USD
CY2011Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	6200000	USD
CY2012Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	5800000	USD
CY2013Q1	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	18197000	USD
CY2012Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	10985000	USD
CY2012Q4	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	21870000	USD
CY2013Q1	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	47735000	USD
CY2013Q1	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	15967000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	17022000	USD
CY2013Q1	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76909000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76520000	USD
CY2013Q1	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	1473000	USD
CY2012Q4	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	1374000	USD
CY2013Q1	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	159007000	USD
CY2012Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	159436000	USD
CY2012Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	658000	shares
CY2013Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	325000	shares
CY2013Q1	regn	Non Cash Interest Expense NonCashInterestExpense	5781000	USD
CY2012Q1	regn	Non Cash Interest Expense NonCashInterestExpense	5543000	USD
CY2013Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	14907000	USD
CY2012Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	12483000	USD
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC

Files In Submission

Name	View Source	Status
0001532176-13-000008-index-headers.html	Edgar Link	pending
0001532176-13-000008-index.html	Edgar Link	pending
0001532176-13-000008.txt	Edgar Link	pending
0001532176-13-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-20130331.xml	Edgar Link	completed
regn-20130331.xsd	Edgar Link	pending
regn-20130331_cal.xml	Edgar Link	unprocessable
regn-20130331_def.xml	Edgar Link	unprocessable
regn-20130331_lab.xml	Edgar Link	unprocessable
regn-20130331_pre.xml	Edgar Link	unprocessable
regn-33113x10q.htm	Edgar Link	pending
regn-ex_311x3312013x10q.htm	Edgar Link	pending
regn-ex_312x3312013x10q.htm	Edgar Link	pending
regn-ex_32x3312013x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2013 Q1 Form 10-Q Financial Statement

#000153217613000008 Filed on May 03, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2013 Q1 Form 10-Q Financial Statement

#000153217613000008 Filed on May 03, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn